The HBsAg-positive group should represent a distinct subgroup with unique clinical features (more frequent extranodal involvement, higher incidence of abnormal liver function and hypoalbuminemia), prognostic features (reduced sensitivity to first-line chemotherapeutic agents, higher rates of early progression, shorter OS and PFS), and genetic features (frequent mutations in MYC, ATM, PTPN6 and epigenetic regulatory genes) compared to the HBsAg-negative group. This evidence concerns the gene MYC and Hypoalbuminemia.